Trending storyDeveloping

PopVax starts Phase 1 trial of COVID vaccine, plans to open-source it

1 report1 sourceupdated 3 hours ago

What happened

AI digest

PopVax's COVID vaccine candidate PVX-001 entered a Phase 1 human trial in Melbourne, Australia, on August 31, 2026, with plans to enroll 36 healthy adults to assess safety, tolerability and immune response. As of October 6, 14 people had been vaccinated and no serious adverse events were reported; follow-up and safety monitoring continue. An October 10 report also said PopVax plans to open-source the work after the trial ends.

Written by AI from the coverage · updated 1 hour ago

LatestOct 10 23:10

As of October 6, 14 people had been vaccinated with no serious adverse events reported; PopVax plans to open-source after the trial ends.

Coverage

Follow the reports to see the story from different sides.

Oct 10

23:10
Hacker News front page
PVX-001: open-source Covid-19 vaccine starts Phase 1 trial
PopVax 的 PVX-001 新冠疫苗候选物于 2026 年 8 月 31 日在澳大利亚墨尔本进入人体 I 期临床试验，计划招募 36 名健康成人。试验评估安全性、耐受性及免疫反应，截至 2026 年 10 月 6 日已有 14 人接种，未报告严重不良事件，随访和安全监测仍在进行。

Heat over time

Not enough continuous observations to draw a trend yet.